搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
5 天
Atara Biotherapeutics股价触及52周新低,跌至6.4美元,面临挑战
在财务展望方面,尽管将目标价从21美元下调至17美元,Canaccord Genuity仍维持Atara的买入评级。该公司将调整原因归结为Ebvallo批准延迟以及可能在2025年初停止CAR-T开发。然而,分析师对解决Ebvallo制造问题表示有信心。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Los Angeles wildfire updates
Colombia tariffs paused
Graham on Jan. 6 pardons
DOJ drops case
Sentenced to 17+ years
IA immigration law blocked
Emil Bove visits Chicago
US lifts bomb restrictions
Shifts view on COVID origins
Win sixth ice dance title
38 hurt on United flight
Wins US figure skating title
‘Walk It Out’ rapper dies
Proposed ban withdrawn
ISR to get 2K-pound bombs
Hack impacted 190M
Indicted for insurrection
Smuggling deaths guilty plea
Israel, Lebanon extend truce
NK tested cruise missiles?
Confirmed to lead Pentagon
Escaped monkeys captured
Nets retire No. 15 jersey
Wins first Grand Slam title
Eagles defeat Commanders
PETA activists arrested
Recalls over 80,000 SUVs
153 war detainees freed
Assault trial begins
反馈